ATRYS HEALTH S.A. EO-01
Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through Diagnosis, Oncology, and Preventive Medicine segments. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; online medical imaging in the fields of r… Read more
ATRYS HEALTH S.A. EO-01 (A2T) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ATRYS HEALTH S.A. EO-01 (A2T) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ATRYS HEALTH S.A. EO-01 - Net Assets Trend (None–None)
This chart illustrates how ATRYS HEALTH S.A. EO-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ATRYS HEALTH S.A. EO-01 (None–None)
The table below shows the annual net assets of ATRYS HEALTH S.A. EO-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ATRYS HEALTH S.A. EO-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ATRYS HEALTH S.A. EO-01 Competitors by Market Cap
The table below lists competitors of ATRYS HEALTH S.A. EO-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sangoma Technologies Corp
NASDAQ:SANG
|
$116.58 Million |
|
Fonciere Inea
PA:INEA
|
$116.59 Million |
|
Diamond Power Infrastructure Limited
NSE:DIACABS
|
$116.63 Million |
|
The Orissa Minerals Development Company Limited
NSE:ORISSAMINE
|
$116.65 Million |
|
Vizsla Royalties Corp.
V:VROY
|
$116.54 Million |
|
China Evergrande Group
F:EV1
|
$116.41 Million |
|
Kuo Yang Construction Co Ltd
TW:2505
|
$116.40 Million |
|
CTT Systems AB
ST:CTT
|
$116.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ATRYS HEALTH S.A. EO-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ATRYS HEALTH S.A. EO-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ATRYS HEALTH S.A. EO-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ATRYS HEALTH S.A. EO-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ATRYS HEALTH S.A. EO-01 (A2T) | €- | N/A | N/A | $116.57 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |